References
- Hassett MJ, O’Malley AJ, Pakes JR, et al. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006;98:1108–17.
- Erban JK, Lau J. On the toxicity of chemotherapy for breast cancer – the need for vigilance. J Natl Cancer Inst 2006;98:1096–7.
- Sharkey RM, Goldenberg DM. Cancer radioimmunotherapy. Immunotherapy 2011;3:349–70.
- Kraeber-Bodéré F, Bodet-Milin C, Rousseau C, et al. Radioimmunoconjugates for the treatment of cancer. Semin Oncol 2014;41:613–22.
- Kim YS, Brechbiel MW. An overview of targeted alpha therapy. Tumour Biol 2012;33:573–90.
- Allen BJ, Huang CY, Clarke RA. Targeted alpha anticancer therapies: update and future prospects. Biologics 2014;8:255–67.
- Seidl C. Radioimmunotherapy with α-particle-emitting radionuclides. Immunotherapy 2014;6:431–58.
- Dahle J, Borrebaek J, Jonasdottir TJ, et al. Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate. Blood 2007;110:2049–56.
- Boswell CA, Brechbiel MW. Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl Med Biol 2007;34:757–78.
- Dahle J, Larsen RH. Targeted alpha-particle therapy with 227Th-labeled antibodies. Curr Radiopharm 2008;1:209–14.
- Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213–23.
- Carrasquillo JA, O’Donoghue JA, Pandit-Taskar N, et al. Phase I pharmacokinetic and biodistribution study with escalating doses of (2)(2)(3)Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2013;40:1384–93.
- Dahle J, Bruland OS, Larsen RH. Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation. Int J Radiat Oncol Biol Phys 2008;72:186–92.
- Torchilin V, Weissig V, eds. Liposomes. 2nd edn. Boston (MA): Oxford University Press; 2003.
- Longchambon L, inventorRadium patent FR679086. 1930.
- Vandenhove H, Verrezen F, Landa ER, eds. Radium. New York, USA: John Wiley & Sons Ltd.; 2010.
- Kirby HW, Salutsky ML. The radiochemistry of radium. In: National Academy of Sciences, National Research Council, Nuclear Science Series, “The Radiochemistry of Radium” (monograph). Available from the Clearinghouse for Federal Scientific and Technical Information, National Bureau of Standards, U.S. Department of Commerce, Springfield, Virginia, USA; 1964.
- Jonasdottir TJ, Fisher DR, Borrebaek J, et al. First in vivo evaluation of liposome-encapsulated 223Ra as a potential alpha-particle-emitting cancer therapeutic agent. Anticancer Res 2006;26:2841–8.
- Henriksen G, Schoultz BW, Michaelsen TE, et al. Sterically stabilized liposomes as a carrier for alpha-emitting radium and actinium radionuclides. Nucl Med Biol 2004;31:441–9.
- Nayak DSL. Biosorption of toxic, heavy, no-carrier-added radionuclides by calcium alginate beads. J Radioanal Nucl Chem 2005;267:59–65.
- Ibanez JP, Umetsu Y. Potential of protonated alginate beads for heavy metals uptake. Hydrometallurgy 2002;64:89–99.
- Simpson N, Van Horne KC, eds. Handbook of Sorbent Extraction Technology: Varia Sample Preparation Products; 1993:30–2. 135 p.
- AG® 50W and AG MP-50, Cation Exchange Resins, Instruction Manual. In: BIO-RAD, ed. Instruction Manual from Bio-Rad Laboratories, Hercules, CA. 1–2.
- SOURCE 30Q and 30S. In: GE Healthcare, ed. Ion exchange media. Instruction Manual from GE Healthcare (18-1106-03 AD). Uppsala, Sweden; 2005:3–4.
- SOURCE 30Q SOURCE 30S. High performance ion exchange chromatography. Data file from GE Healthcare, Uppsala, Sweden (18-1107-12-AB); 2007:1.
- CHT™ Ceramic Hydroxyapatite, Instruction Manual. In: BIO-RAD, ed. Instruction Manual from from Bio-Rad Laboratories, Hercules, CA. 3–4..
- Smiciklas I, Onjia A, Raicević S, et al. Factors influencing the removal of divalent cations by hydroxyapatite. J Hazard Mater 2008;152:876–84.
- Reed TB, Breck DW. Crystalline zeolites. II. Crystal structure of synthetic zeolite, type A. J Am Chem Soc 1956;78:5972–7.
- Piotrowska A, Leszczuk E, Bruchertseifer F, et al. Functionalized NaA nanozeolites labeled with (224,225)Ra for targeted alpha therapy. J Nanopart Res 2013;15:2082–93.
- AppliChem. Biological buffers. Information sheet from AppliChem, Darmstadt, Germany; 2008:6.
- Rothe J, Denecke MA, Neck V, et al. XAFS investigation of the structure of aqueous thorium(iv) species, colloids, and solid thorium(iv) oxide/hydroxide. Inorg Chem 2002;41:249–58.